Subjects: Antibodies, Monoclonal, Humanized -- therapeutic use - Digital Collections - National Library of Medicine Search Results

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

NLM Digital Collections

Start Over Subjects Antibodies, Monoclonal, Humanized -- therapeutic use

1. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):: Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
United States

2. Tezepelumab for severe asthma: final report

Author(s):: Rind, David M., author
Campbell, Jonathan D., author
Herce-Hagiwara, Belén, author
Herron-Smith, Serina, author
Fluetsch, Noemi, author
Pearson, Steven D., author
McQueen, R. Brett, author
Gutierrez, Eric, (Of University of Colorado), author
Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, February 13, 2023
Subject(s):: Antibodies, Monoclonal, Humanized -- therapeutic use
Asthma -- drug therapy
United States

3. Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity

Author(s):: Kolbe, Allison, author
Publication:: Washington, DC : Office of the Assistant Secretary for Planning and Evaluation, Office of Science & Data Policy, December 2021
Subject(s):: Antibodies, Monoclonal, Humanized -- therapeutic use
COVID-19 Drug Treatment
Healthcare Disparities
Social Vulnerability
Urban Population
Vulnerable Populations
United States

4. Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report

Publication:: [Boston, Massachusetts] : Institute for Clinical and Economic Review, July 17, 2017
Subject(s):: Anabolic Agents -- therapeutic use
Antibodies, Monoclonal, Humanized -- therapeutic use
Osteoporosis, Postmenopausal -- drug therapy
Parathyroid Hormone-Related Protein -- therapeutic use
United States